CHICAGO, July 16 (Reuters) - An experimental Alzheimer's disease drug developed by Acumen Pharmaceuticals ABOS.O targeting a novel form of the toxic protein beta amyloid in the brain passed an early ...
Today’s businesses need to adapt faster than ever, global competition is fierce and, according to a recent article in the New York Times, retirement rates are accelerating. The next generation of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results